A Phase 1 interventional study of PHST001 and Paclitaxel in Advanced Solid Tumors, Ovarian Cancer and Endometrial Cancer, sponsored by Pheast Therapeutics. Recruiting at 20 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-05.
Sponsored by Pheast Therapeutics · Phase 1, Interventional, and Treatment
Drug: Paclitaxel · Drug: Topotecan · Drug: Doxorubicin · Drug: FOLFIRI · Drug: FOLFOX · Drug: Gemcitabine · Biological: Mirvetuximab Soravtansine · Biological: Trastuzumab Deruxtecan
PHST001 Monotherapy · PHST001 + Paclitaxel · PHST001 + Topotecan · PHST001 + Doxorubicin · PHST001 + FOLFIRI · PHST001 + FOLFOX · PHST001 + Gemcitabine · PHST001 + Mirvetuximab Soravtansine · PHST001 + Trastuzumab Deruxtecan · Mirvetuximab Soravtansine Monotherapy
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies testing mirvetuximab soravtansine in Ovarian Neoplasms — 5 open to participants now, 8 under way, 1 of them phase 3. mirvetuximab soravtansine · Ovarian Neoplasms.
Among the 12 studies testing mirvetuximab soravtansine in Ovarian Neoplasms, this one is the 2nd largest by planned enrollment, is one of 2 that started in 2025, is one of 3 in phase 1, and was the 10th registered.
3,389 studies on the registry are indexed under Ovarian Neoplasms; 791 are open to participants now.
Browse Ovarian Neoplasms studies →5 of the 12 studies testing mirvetuximab soravtansine in Ovarian Neoplasms are open now, in 9 countries. Recruiting first, the newest first:
AbbVie · Sites in United States, Australia, Belgium and 5 more countries
Ages 18+ · Women only
University of Colorado, Denver · Sites in United States
Ages 18–100 · Women only
University of Alabama at Birmingham · Sites in United States
Ages 18+ · Women only
Tongji Hospital · Sites in China
Ages 18+ · Women only
By country, each count listing its studies:
mirvetuximab soravtansine: first FDA approval 2022 (ELAHERE), first EMA approval 2024. What it is approved for, and how studies give it, is on its page →
Of the 601 Ovarian Neoplasms studies recruiting now, 438 (73%) set no upper age limit and 107 (18%) stop at 75 or younger; 39 take children under 18; 45 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 7 · Phase 3 2
First in 2016; this study’s year is marked. 2 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 426 is above the median of 54 across 2,555 interventional studies indexed under Ovarian Neoplasms.
Median enrollment 80 across the 12 interventional studies. Of the 4 that completed or were terminated, 2 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 12 have an industry lead sponsor. The 9 most frequent:
This is the only study on the registry with Pheast Therapeutics as lead sponsor.
Pheast Therapeutics has 1 study filed under Ovarian Neoplasms — fewer than ten, so there is no comparison to draw.
3 of the studies testing mirvetuximab soravtansine in Ovarian Neoplasms that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05445778Phase 3AbbVieMirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer | 2027-04 |
| NCT05456685AbbVieMirvetuximab Soravtansine (MIRV) With Carboplatin in Second-line Treatment of Folate Receptor Alpha (FRα) Expressing, Platinum-sensitive Epithelial Ovarian Cancer | 2026-11 |
| NCT04606914University of Alabama at BirminghamStudy of Carboplatin and Mirvetuximab Soravtansine in First-Line Treatment of Patients Receiving Neoadjuvant Chemotherapy With Advanced-Stage Ovarian, Fallopian Tube or Primary Peritoneal Cancer | 2027-07 |
Add all 3 to your calendar (.ics) → With an account.
Among the 12 studies testing mirvetuximab soravtansine in Ovarian Neoplasms, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a multi-center, first-in-human (FIH), open-label, Phase 1a/1b dose escalation and dose expansion study to assess the safety, PK, pharmacodynamics, and antitumor activity of PHST001 monotherapy (Phase 1a) or in combination with anticancer therapies (Phase 1b) in adult participants with advanced relapsed and/or refractory solid tumors (including but not limited to CNS tumors in Phase 1a only). Phase 1b will include the following cohorts 1) tumor-specific cohorts for participants with advanced relapsed and/or refractory ovarian cancer, endometrial cancer, and cholangiocarcinoma, 2) a randomized cohort for participants with ovarian cancer who will receive PHST001 in combination with mirvetuximab soravtansine, 3) a cohort for participants with advanced/metastatic breast cancer who will receive PHST001 in combination with trastuzumab deruxtecan and 4) a cohort of patients who consent to additional biomarker studies.
The study's primary objectives are to evaluate the safety and tolerability of PHST001 and determine the RP2D (Recommended Phase 2 dose) of PHST001 as monotherapy and in combination with anticancer therapies, as well as to assess the anti-tumor activity of PHST001 in combination with anticancer therapies in Phase 1b.
The criteria were revised on the registry on Oct 5, 2026. See what changed
Key Inclusion Criteria:
Key Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive PHST001 monotherapy administered once every 3 weeks (Q3W). In Phase 1a, PHST001 will be evaluated in sequential dose-escalation cohorts at planned dose levels of 0.1, 0.3, 1.0, 2.0, 4.0, 6.0, 9.0, 18.0, and 36.0 mg/kg. Dose levels may be modified or additional dose levels evaluated based on emerging safety, pharmacokinetic, pharmacodynamic, and antitumor activity data. Participants in the Phase 1b biomarker cohort may also receive PHST001 monotherapy.
Biological: PHST001
Participants will receive PHST001 in combination with paclitaxel. The combination will initially be evaluated in a Phase 1b safety run-in group. Following safety clearance, the combination may be evaluated in tumor-specific expansion cohorts, including participants with ovarian carcinoma, endometrial carcinoma, or cholangiocarcinoma, and/or in the biomarker cohort.
Biological: PHST001 · Drug: Paclitaxel
Participants will receive PHST001 in combination with topotecan. The combination will initially be evaluated in a Phase 1b safety run-in group. Following safety clearance, the combination may be evaluated in the ovarian carcinoma expansion cohort and/or biomarker cohort.
Biological: PHST001 · Drug: Topotecan
Participants will receive PHST001 in combination with doxorubicin. The combination will initially be evaluated in a Phase 1b safety run-in group. Following safety clearance, the combination may be evaluated in ovarian carcinoma or endometrial carcinoma expansion cohorts and/or the biomarker cohort.
Biological: PHST001 · Drug: Doxorubicin
Participants will receive PHST001 in combination with FOLFIRI (5-fluorouracil, folinic acid, and irinotecan). The combination will initially be evaluated in a Phase 1b safety run-in group. Following safety clearance, the combination may be evaluated in the cholangiocarcinoma expansion cohort and/or biomarker cohort.
Biological: PHST001 · Drug: FOLFIRI
Participants will receive PHST001 in combination with FOLFOX (5-fluorouracil, folinic acid, and oxaliplatin). The combination will initially be evaluated in a Phase 1b safety run-in group. Following safety clearance, the combination may be evaluated in the cholangiocarcinoma expansion cohort and/or biomarker cohort.
Biological: PHST001 · Drug: FOLFOX
Participants will receive PHST001 in combination with gemcitabine. The combination will initially be evaluated in a Phase 1b safety run-in group. Following safety clearance, the combination may be evaluated in ovarian carcinoma or cholangiocarcinoma expansion cohorts and/or the biomarker cohort.
Biological: PHST001 · Drug: Gemcitabine
Participants will receive PHST001 in combination with mirvetuximab soravtansine. The combination will initially be evaluated in a Phase 1b safety run-in group. Following safety clearance, the combination may be evaluated in the ovarian carcinoma expansion cohort and/or in the biomarker cohort. Half of the participants in the randomized ovarian carcinoma cohort may be randomly assigned to receive PHST001 in combination with mirvetuximab soravtansine.
Biological: PHST001 · Biological: Mirvetuximab Soravtansine
Participants will receive PHST001 in combination with trastuzumab deruxtecan. The combination will initially be evaluated in a Phase 1b safety run-in group. Following safety clearance, the combination may be evaluated in participants with advanced or metastatic breast cancer and/or in the biomarker cohort.
Biological: PHST001 · Biological: Trastuzumab Deruxtecan
Participants with ovarian carcinoma enrolled in the randomized Phase 1b expansion cohort will be randomized 1:1 to receive mirvetuximab soravtansine monotherapy or mirvetuximab soravtansine in combination with PHST001. Participants assigned to this arm will receive mirvetuximab soravtansine monotherapy.
Biological: Mirvetuximab Soravtansine
PHST001 is an anti-CD24 macrophage checkpoint inhibitor, administered as IV infusions every 3-weeks (Q3W) dosing intervals.
Paclitaxel used as per standard of care.
Also known as: Taxol
Topotecan used as per standard of care.
Also known as: Hycamtin
Doxorubicin used as per standard of care.
Also known as: Adriamycin
FOLFIRI used as per standard of care.
Also known as: folinic acid (leucovorin), fluorouracil (5-FU), and irinotecan combination
FOLFOX used as per standard of care.
Also known as: folinic acid (leucovorin), fluorouracil (5-FU), and oxaliplatin combination
Gemcitabine used as per standard of care.
Also known as: Gemzar
Mirvetuximab soravtansine used as per standard of care.
Also known as: MIRV, Elahere
Trastuzumab deruxtecan used as per standard of care.
Also known as: T-DXd, Enhertu
Frequency of Dose-Limiting Toxicities (DLTs) to assess the safety and tolerability of PHST001 as monotherapy (Phase 1a) or in combination with anticancer therapy (Phase 1b)
Based on toxicities observed
Time frame: From first dose of PHST001 through 21 days after the first dose of PHST001
Frequency of Serious Adverse Events (SAEs) to assess the safety and tolerability of PHST001 as monotherapy (Phase 1a) or in combination with anticancer therapy (Phase 1b)
Based on toxicities observed
Time frame: From signed consent up to 90 days after the last dose of PHST001
Frequency of Treatment Emergent Adverse Events (TEAEs) to assess the safety and tolerability of PHST001 as monotherapy (Phase 1a) or in combination with anticancer therapy (Phase 1b)
Based on toxicities observed
Time frame: From first dose up to 90 days after the last dose of PHST001
Frequency of Treatment Related Adverse Events (TRAEs) to assess the safety and tolerability of PHST001 as monotherapy (Phase 1a) or in combination with anticancer therapy (Phase 1b)
Based on toxicities observed
Time frame: From first dose up to 90 days after the last dose of PHST001
Frequency of Adverse Events of Special Interest (AESIs) to assess the safety and tolerability of PHST001 as monotherapy (Phase 1a) or in combination with anticancer therapy (Phase 1b)
Based on toxicities observed
Time frame: From first dose up to 90 days after the last dose of PHST001
Frequency of AEs Leading to Dose Interruption or Treatment Discontinuation and AEs Leading to Death to assess the safety and tolerability of PHST001 as monotherapy (Phase 1a) or in combination with anticancer therapy (Phase 1b)
Based on toxicities observed
Time frame: From first dose up to 90 days after the last dose of PHST001
Overall Response Rate (ORR) based on RECIST v1.1 to assess the preliminary antitumor activity of PHST001 in combination with anticancer therapy (Phase 1b non-randomized cohorts only)
Defined as the proportion of subjects with confirmed complete response (CR) or partial response (PR); a confirmed response is a response that persists on repeat-imaging ≥ 4 weeks after initial documentation of response.
Time frame: From screening and during treatment up to 2 years
Progression-Free Survival (PFS) based on RECIST v1.1 to assess the preliminary antitumor activity of PHST001 in combination with anticancer therapy (Phase 1b randomized cohort only)
Defined as the time from first dose of PHST001 to first documentation of radiographic disease progression or death, whichever occurs first.
Time frame: From screening and during treatment up to 2 years
Overall Response Rate (ORR) based on RECIST v1.1 (or RANO for primary CNS Tumors) to assess the preliminary antitumor activity of PHST001 as monotherapy (Phase 1a) and in combination with anticancer therapy (Phase 1b - randomized cohort only)
Defined as the proportion of subjects with confirmed complete response (CR) or partial response (PR); a confirmed response is a response that persists on repeat-imaging ≥ 4 weeks after initial documentation of response.
Time frame: From screening and during treatment up to 2 years
Duration of Response (DOR) based on RECIST v1.1 (or RANO for primary CNS Tumors) to assess the preliminary antitumor activity of PHST001 as monotherapy (Phase 1a) and in combination with anticancer therapy (Phase 1b)
Defined as time from date of first objective response (either CR or PR) to first documentation of radiographic disease progression.
Time frame: From screening and during treatment up to 2 years
Best Overall Response (BOR) based on RECIST v1.1 (or RANO for primary CNS Tumors) to assess the preliminary antitumor activity of PHST001 as monotherapy (Phase 1a) and in combination with anticancer therapy (Phase 1b)
Defined as the best response recorded for a participant across all time-point assessments from the start of treatment until disease progression or end of treatment.
Time frame: From screening and during treatment up to 2 years
Progression-Free Survival (PFS) based on RECIST v1.1 (or RANO for primary CNS Tumors) to assess the preliminary antitumor activity of PHST001 as monotherapy (Phase 1a) and in combination with anticancer therapy (Phase 1b - non-randomized cohorts only) .
Defined as the time from first dose of PHST001 to first documentation of radiographic disease progression or death, whichever occurs first.
Time frame: From screening and during treatment up to 2 years
Overall Survival (OS) based on RECIST v1.1 (or RANO for primary CNS Tumors) to assess the preliminary antitumor activity of PHST001 as monotherapy (Phase 1a) and in combination with anticancer therapy (Phase 1b).
Defined as the time from first dose of PHST001 to the date of death.
Time frame: From screening and during treatment up to 2 years
Maximum Observed Concentration (Cmax) to characterize the serum PK of PHST001 as monotherapy (Phase 1a) or in combination with anticancer therapy (Phase 1b).
Defined as the maximum blood concentration of a dose of PHST001
Time frame: From treatment until 90 days after last dose of PHST001
Time to Maximum Concentration (tmax) to characterize the serum PK of PHST001 as monotherapy (Phase 1a) or in combination with anticancer therapy (Phase 1b)
Defined as the time required for a dose of PHST001 to reach its maximum blood concentration (Cmax) after administration.
Time frame: From treatment until 90 days after last dose of PHST001
Concentration at the End of a Dosing Interval (Ctrough) to characterize the serum PK of PHST001 as monotherapy (Phase 1a) or in combination with anticancer therapy (Phase 1b)
Defined as the blood concentration of a dose of PHST001 at the end of the dosing interval (just prior to next drug administration).
Time frame: From treatment until 90 days after last dose of PHST001
Area Under the Concentration-time Curve (AUC) to characterize the serum PK of PHST001 as monotherapy (Phase 1a) or in combination with anticancer therapy (Phase 1b)
Defined as the total PHST001 exposure over time, calculated as the integral of the plasma concentration-time profile.
Time frame: From treatment until 90 days after last dose of PHST001
Volume of Distribution at Steady-state (Vss) to characterize the serum PK of PHST001 as monotherapy (Phase 1a) or in combination with anticancer therapy (Phase 1b)
Defined as how widely PHST001 spreads throughout the body once things have stabilized after a dose has been administered.
Time frame: From treatment until 90 days after last dose of PHST001
Clearance (CL) to characterize the serum PK of PHST001 as monotherapy (Phase 1a) or in combination with anticancer therapy (Phase 1b)
Defined as the rate at which the body "cleans out" a dose of PHST001 from the bloodstream.
Time frame: From treatment until 90 days after last dose of PHST001
Terminal Elimination Half-life (t½) to characterize the serum PK of PHST001 as monotherapy (Phase 1a) or in combination with anticancer therapy (Phase 1b)
Defined as the time it takes for the amount of PHST001 in the body to drop by half during the final phase of elimination.
Time frame: From treatment until 90 days after last dose of PHST001
Started Mar 2025 (actual). Primary completion is estimated for Apr 2029, 49 months after the start.
Of 210 industry-sponsored phase 1 interventional studies under Ovarian Neoplasms, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 65. This study's planned 49 months is close to that.
Counting every sponsor, half of 380 studies reached it within 50 months; a quarter within 32 and three quarters within 76.
How these figures are worked out, and which studies are left out of them.
Drug: Paclitaxel · Drug: Topotecan · Drug: Doxorubicin · Drug: FOLFIRI · Drug: FOLFOX · Drug: Gemcitabine · Biological: Mirvetuximab Soravtansine · Biological: Trastuzumab Deruxtecan
PHST001 Monotherapy · PHST001 + Paclitaxel · PHST001 + Topotecan · PHST001 + Doxorubicin · PHST001 + FOLFIRI · PHST001 + FOLFOX · PHST001 + Gemcitabine · PHST001 + Mirvetuximab Soravtansine · PHST001 + Trastuzumab Deruxtecan · Mirvetuximab Soravtansine Monotherapy
Drug: Paclitaxel · Drug: Topotecan · Drug: Doxorubicin · Drug: FOLFIRI · Drug: FOLFOX · Drug: Gemcitabine · Biological: Mirvetuximab Soravtansine · Biological: Trastuzumab Deruxtecan
PHST001 Monotherapy · PHST001 + Paclitaxel · PHST001 + Topotecan · PHST001 + Doxorubicin · PHST001 + FOLFIRI · PHST001 + FOLFOX · PHST001 + Gemcitabine · PHST001 + Mirvetuximab Soravtansine · PHST001 + Trastuzumab Deruxtecan · Mirvetuximab Soravtansine Monotherapy
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Mirvetuximab soravtansine